Pancreatic Cancer Model

Indication / Application

Evaluation of novel anti-tumor therapeutics, validation of stroma-targeted or extracellular matrix-disrupting agents, preclinical profiling of combination immunotherapies (e.g., immune checkpoint inhibitors), and investigation of systemic metastatic pathways.

Modeling Method

1. Xenograft & Syngeneic Platforms (CDX/PDX):

• Subcutaneous Model: Inoculation of established human pancreatic cancer lines (e.g., PANC-1, BxPC-3, MIA PaCa-2) or patient-derived tumor fragments into the flank of immunodeficient mice for reproducible, high-throughput tumor volume kinetics.

• Orthotopic Model: Under high-magnification microsurgery, a precise volume of luciferase-tagged tumor cells or fragmented tissue is micro-injected directly into the tail of the pancreas to mimic the authentic anatomical and architectural microenvironment.

2. Genetically Engineered Mouse Models (GEMM):

• Maintenance and profiling of spontaneous PDAC models (e.g., LSL-KrasG12D/+, LSL-Trp53R172H/+, Pdx1-Cre [KPC] models) to evaluate therapies against endogenous, immune-competent tumor progression.

Clinical Relevance

• Microenvironmental Fidelity: While subcutaneous models provide highly reproducible data for initial screenings, our orthotopic and GEMM platforms accurately recapitulate the extensive fibrotic stroma (desmoplasia) and hypovascularity characteristic of human pancreatic tumors, providing a rigorous clinical barrier for therapeutic penetration.

• Translational Metastasis: Orthotopic models faithfully simulate human clinical progression, showcasing spontaneous, aggressive metastasis to the liver, peritoneum, and regional lymph nodes, which is essential for validating anti-metastatic therapeutics.

Key Evaluation Endpoints

In Vivo / Longitudinal Monitoring

• Bioluminescence Imaging (BLI): Non-invasive tracking of orthotopic tumor growth, local tissue invasion, and distant metastatic spread using luciferase-expressing cell lines.

• High-Resolution Micro-Ultrasound: Serial real-time imaging to quantify intra-pancreatic tumor volume, structural boundaries, and localized vascular perfusion.

• Cachexia & Survival Analysis: Meticulous tracking of animal body weight, body composition changes, and overall survival curves.

Histopathology & Immunophenotyping (Gold Standard)

• Histomorphological Assessment: Standard H&E and Masson’s Trichrome staining to quantify tumor differentiation, desmoplastic stroma density, and collagen deposition.

• Immunohistochemistry (IHC) & Immunofluorescence (IF):

  • Proliferation & Apoptosis: Ki-67 scoring and TUNEL staining.

  • Stromal & Extracellular Matrix Elements: alpha-SMA (activated pancreatic stellate cells), Collagen I, and Hyaluronic Acid accumulation profiling.

  • Immune Infiltration (Syngeneic/GEMM): CD8+ T cells, regulatory T cells (Tregs), and Myeloid-Derived Suppressor Cells (MDSCs).

Molecular & Systemic Biomarkers

• Gene Expression Profiles: RT-qPCR and Western Blot analysis tracking changes in key therapeutic targets and signaling pathways (e.g., KRAS, p53, SHH, TGF-beta).

• Serum Biomarker Quantitation: Serial ELISA monitoring of circulating tumor-associated antigens (such as CA19-9) and systemic inflammatory cytokines.